Nuvalent (NUVL) Non Operating Income (2020 - 2026)
Nuvalent's (NUVL) quarterly Non Operating Income came in at $10.3 million in Q1 2026, down 0.88% YoY from $10.4 million in Q1 2025, and down 73.53% on a QoQ basis from $38.9 million in Q4 2025.
Nuvalent (NUVL) Non Operating Income (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Non Operating Income data on file, last reported at $10.3 million in Q1 2026.
- Quarterly Non Operating Income fell 0.88% year-over-year to $10.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.7 million (up 114.64% YoY) and the FY2025 annual result came in at $44.7 million, up 16.75% from the prior year.
- Non Operating Income retreated to $10.3 million in Q1 2026, from $38.9 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $38.9 million in Q4 2025 to a low of -$9.6 million in Q3 2025.
- A 5-year average of $6.5 million and a median of $5.1 million in 2023 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income soared 67100.0% — and 2024, when it plunged 255.2%.
- Tracing NUVL's Non Operating Income over 5 years: stood at $3.2 million in 2022, then jumped by 156.45% to $8.1 million in 2023, then soared by 60.18% to $13.0 million in 2024, then soared by 198.11% to $38.9 million in 2025, then tumbled by 73.53% to $10.3 million in 2026.
- The last three Non Operating Income figures came in at $10.3 million (Q1 2026), $38.9 million (Q4 2025), and -$9.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - | 10.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.30 Mn |
| Dec 31, 2025 | 38.89 Mn |
| Sep 30, 2025 | -9.61 Mn |
| Jun 30, 2025 | 11.10 Mn |
| Mar 31, 2025 | 10.39 Mn |
| Dec 31, 2024 | 13.05 Mn |
| Sep 30, 2024 | -7.97 Mn |
| Jun 30, 2024 | 8.15 Mn |
| Mar 31, 2024 | 8.49 Mn |
| Dec 31, 2023 | 8.15 Mn |
| Sep 30, 2023 | 5.14 Mn |
| Jun 30, 2023 | 4.97 Mn |
| Mar 31, 2023 | 5.02 Mn |
| Dec 31, 2022 | 3.18 Mn |
| Sep 30, 2022 | 672,000.00 |
| Jun 30, 2022 | 267,000.00 |
| Mar 31, 2022 | 139,000.00 |
| Dec 31, 2021 | 89,000.00 |
| Sep 30, 2021 | 1,000.00 |
| Jun 30, 2021 | 12,000.00 |